For Corporate Acquirers
The M&A Report ($25,000 per target) is an independent read of the public record alongside banker- and target-supplied materials, covering clinical adoption, manufacturing integration, regulatory alignment and IP, reviewed by a physician and a biomedical engineer. Factual claims are cited to their sources.
Multi-Target Screening
Run a Quick Screen on each bolt-on, build-vs-buy candidate or strategic option: six independent signals per company, each linked to its source records, with no composite score and no ranking verdict.
De-Risk Your Pipeline
Surface the risks before engagement letters.
What We Find
Six of the areas the report reads.
Diligence domains per full report
Companies in our substrate
Public data sources
Review on full reports
Does the platform roadmap align with target capabilities? The report reads the target's technical record so fit questions are on the table early.
Quality, scale, and supplier consolidation questions, read from recalls, FDA records and supplied materials.
FDA pathway and compliance record. A misread regulatory position can add months and material cost after close.
Patent scope, assignees, and freedom-to-operate questions to raise with counsel.
Reimbursement alignment and customer overlap, read against comparable companies from a substrate of 3,900+ biomedical companies.
Will clinicians adopt the integrated solution? Workflow disruption is a post-close risk a technical review can miss.
Pricing
An automated Quick Screen for inbound targets, the $20,000 Diligence Report, and the $25,000 M&A Report for finalists.
Evaluating several targets? We can scope reports across your pipeline. Contact us →
A missed clinical or technical question can cost far more after close than the diligence that would have surfaced it.
Deal Lifecycle
From target screening to the board decision
Quick Screen on inbound targets to identify clinical and manufacturing red flags early
M&A Report on finalists, with integration risk and reference-contact review
Report findings feed your own legal, financial and quality diligence
A 60-minute session on the findings
Findings in front of the board, with sources attached
How we'd diligence a target
We'd rather show you the framework run on cases your corp-dev team already knows than ask you to trust an unnamed testimonial. Each card is a public retrospective and the questions the public record raised.
Recalls of polyethylene implant components over a packaging defect (2021–22), then Chapter 11 in 2024. We walk the questions a corp-dev team could put to a quality team.
Read the retrospective →An October 2021 FDA warning letter, after Owlet’s July 2021 SPAC listing, said the Smart Sock was being marketed as an uncleared medical device, and Owlet stopped selling it in the US. We walk the classification questions visible in the public record.
Read the retrospective →An early FDA-authorized prescription digital therapeutic, a 2021 SPAC listing and a 2023 bankruptcy. We trace the payer-coverage and prescribing-economics questions visible in the public record.
Read the retrospective →These are public retrospectives, not client engagements. They let buyers see the framework before signing.
If you evaluate several targets a year, we can scope M&A Reports across your pipeline. Every report is independent of deal parties, cited to its sources and drawn from our proprietary multi-source substrate.
Talk to Arvind Ravinutala, MD →Talk to Arvind Ravinutala, MD, about the M&A Report, or start with a Quick Screen on inbound targets.
Clinical, manufacturing, and regulatory risks to check before an acquisition. Created by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the ChecklistNo email required. No paywall.